Mark N. Feinglos, MD, CM
Division Chief, Endocrinology, Metabolism, and Nutrition
Departments / Divisions- Medicine / Medicine-Endocrinology and Metabolism
- Pathology
- Psychiatry
Address
DUMC 3921
Durham, NC 27710
Appointment Telephone
919-620-5300
Office Telephone
919-684-4005
Fax Telephone
919-681-8477
- MD, CM, McGill University Faculty of Medicine (Canada), 1973
- Internal Medicine, Duke University Medical Center, 1973-1975
- Endocrinology, Duke University Medical Center, 1975-1978
Clinical Interests
Diabetes mellitus, with particular interest in patients with unstable diabetes, insulin resistance, insulin allergy, poorly controlled type 2 diabetes,
hypothyroidism, hyperthyroidism
Research Interests
I am interested in the etiology and treatment of type 2 diabetes mellitus. For many years, we have studied the role of the autonomic nervous system in the pathophysiology of type 2 diabetes in humans and a murine model. We have also studied the mechanism of action of dietary therapy and a variety of pharmacological agents in the treatment of type 2 diabetes.
Dr. Richard Surwit of the Department of Psychiatry and Behavioral Sciences and I are conducting a variety of human studies on the relationship of stress hormones and various food additives on the development and expression of type 2 diabetes. I am also engaged in a number of multicenter studies of the effect of various treatment plans on cardiovascular outcomes in type 2 diabetes patients. In addtion, my group continues to evaluate new treatment modalities for patients with type 2 diabetes, including new types of insulin, GLP-1 analogs, new classes of oral agents, and combinations of drugs.
I am frequently consulted by industry to evaluate new therapeutic modalities. I most frequently peer review scientific articles concerning the treatment of type 2 diabetes.
Key words: diabetes mellitus, stress, sulfonylureas, oral hypoglycemics, insulin, murine diabetes, diabetic diet
This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.
- Amylin Pharmaceuticals, Inc.
- AstraZeneca
- Bristol-Myers Squibb
- Eli Lilly & Co.
- GlaxoSmithKline
- Merck Sharpe & Dohme (Merck & Co, USA)
- Novo Nordisk
- Procter & Gamble Company
- Prodigy Diabetes Care, LLC
- Sanofi-Aventis
- Tethys
